51. CaV1.3-selective L-type calcium channel antagonists as potential new therapeutics for Parkinson's disease
- Author
-
Brendon E. Dusel, Soosung Kang, Chi Hao Luan, Garry Cooper, Richard B. Silverman, Sara Fernandez Dunne, and D. James Surmeier
- Subjects
Parkinson's disease ,Patch-Clamp Techniques ,Calcium Channels, L-Type ,Drug Evaluation, Preclinical ,General Physics and Astronomy ,Pharmacology ,General Biochemistry, Genetics and Molecular Biology ,Cav1.3 ,Small Molecule Libraries ,Structure-Activity Relationship ,medicine ,Animals ,Humans ,L-type calcium channel ,Patch clamp ,Multidisciplinary ,Crystallography ,biology ,Voltage-dependent calcium channel ,Calcium channel ,Antagonist ,Parkinson Disease ,General Chemistry ,medicine.disease ,Calcium Channel Blockers ,High-Throughput Screening Assays ,Rats ,Electrophysiology ,HEK293 Cells ,Barbiturates ,biology.protein ,Rabbits - Abstract
L-type calcium channels expressed in the brain are heterogeneous. The predominant class of L-type calcium channels has a Ca(V)1.2 pore-forming subunit. L-type calcium channels with a Ca(V)1.3 pore-forming subunit are much less abundant, but have been implicated in the generation of mitochondrial oxidant stress underlying pathogenesis in Parkinson's disease. Thus, selectively antagonizing Ca(V)1.3 L-type calcium channels could provide a means of diminishing cell loss in Parkinson's disease without producing side effects accompanying general antagonism of L-type calcium channels. However, there are no known selective antagonists of Ca(V)1.3 L-type calcium channel. Here we report high-throughput screening of commercial and 'in-house' chemical libraries and modification of promising hits. Pyrimidine-2,4,6-triones were identified as a potential scaffold; structure-activity relationship-based modification of this scaffold led to 1-(3-chlorophenethyl)-3-cyclopentylpyrimidine-2,4,6-(1H,3H,5H)-trione (8), a potent and highly selective Ca(V)1.3 L-type calcium channel antagonist. The biological relevance was confirmed by whole-cell patch-clamp electrophysiology. These studies describe the first highly selective Ca(V)1.3 L-type calcium channel antagonist and point to a novel therapeutic strategy for Parkinson's disease.
- Published
- 2012